Dapagliflozin treatment of patients with CKD without diabetes across different albuminuria levels.

Suspected de novo heart failure in outpatient care associated with high risk

Cardiovascular mortality and morbidity in patients with T2D following initiation of SGLT2i versus other glucose-lowering drugs

Lower Risk of Heart Failure and Death in Patients Initiated on SGLT2i Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors)

Prevalence, outcomes and costs of a contemporary, multinational population with heart failure.

Prevalence, outcomes, and cost of chronic kidney disease in a contemporary population of 2·4 million patients from 11 countries

Mortality, Outcomes, Costs, and Use of Medicines Following a First Heart Failure Hospitalization:

Heart Failure Drug Treatment—Inertia, Titration, and Discontinuation: A Multinational Observational Study (EVOLUTION HF)

Heart failure drug titration, discontinuation, mortality and heart failure hospitalization risk: a multinational observational study (US, UK and Sweden)

Heart failure and chronic kidney disease manifestation and mortality risk associations in type 2 diabetes: A large multinational cohort study

Lower heart failure and chronic kidney disease risks associated with sodium-glucose cotransporter-2 inhibitor use in Japanese type 2 diabetes patients without established cardiovascular and renal diseases

Mortality, Health Care Burden, and Treatment of CKD: A Multinational, Observational Study